1. Taiwan, Province of China Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Ever Supreme Bio Technology Co., Ltd

Ever Supreme Bio Technology Co., Ltd

6712.TWO
Ever Supreme Bio Technology Co., LtdTW flagTaipei Exchange
175.50
TWD
-7.50
- -
17.86BMarket Cap
Ever Supreme Bio Technology Co., Ltd
6712.TWO
(Taipei Exchange)

Recent

price

175.50

P/E

ratio

- -

div

yld

- -

ROIC.AI

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
- -
- -
0.13
0.82
4.63
6.59
8.03
10.02
- -
10.98
Revenue per Share
-0.03
-0.54
-0.85
-1.09
-1.24
3.9
2.11
5.71
3.94
- -
4.63
Basic EPS, GAAP
-0.1
-0.69
-1.2
-1.5
-2.31
1.38
3.3
4.4
4.67
- -
5.73
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
3.25
1.44
4.72
- -
- -
Dividend per Share
6.48
6.16
5.69
4.25
3.42
7.25
9.67
10.9
12.71
- -
10.8
Book Value per Share
6.48
6.09
11.42
9.72
8.95
19.91
18.71
19.39
19.15
- -
16.33
Tangible Book Value per Share
15
57
81
86
86
95
95
94
93
- -
93
Basic Weighted Avg Shares
- -
- -
- -
11
71
439
628
758
934
1,018
1,018
Sales/Revenue/Turnover
- -
- -
- -
-1,252.31
-222.54
26.48
45.23
44.53
49.86
43.14
43.14
Operating Margin (%)
- -
1
7
17
32
36
36
32
31
23
23
Depreciation Expense
- -
-31
-69
-94
-107
370
201
539
367
429
429
Net Income, GAAP
- -
- -
- -
- -
- -
6.86
24
13.42
20.29
18.1
18.1
Effective Tax Rate (%)
- -
- -
- -
-870.87
-151.32
84.22
31.99
71.12
39.33
42.2
42.2
Profit Margin (%)
98
307
789
598
438
1,370
1,292
1,289
894
330
330
Working Capital
- -
- -
- -
32
33
23
13
1
1
28
28
LT Debt
100
349
931
846
781
1,898
1,792
1,843
1,794
1,527
1,527
Total Equity
- -
- -
- -
- -
- -
7.79
11.43
15.74
19.74
20.68
20.68
Return on Invested Capital (%)
- -
- -
- -
- -
- -
69.93
24.24
54.67
33.05
38.64
38.64
Return on Capital (%)
- -
-13.65
-17
-22.81
-32.36
75.34
24.98
55.32
33.17
39.3
39.3
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Jun'25
Sep'25
Dec'25
ST Debt
11
10
10
LT Borrowings
- -
- -
- -
LT Finance Leases
34
31
28
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
92
92
92
Market Capitalization
13,753
16,370
14,472

Working Capital

FRC

•

in mil. unless spec.
Jun'25
Sep'25
Dec'25
Total Current Assets
514
610
753
Cash, Cash Equivalents & STI
283
355
436
Accounts Receivable, Net
101
154
229
Inventories
105
84
76
Total Current Liabilities
365
361
423
Payables & Accruals
- -
- -
- -
ST Debt
11
10
10
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
24.55%
-14.92%
Free Cash Flow
- -
6.56%
22.04%
Net Income, GAAP
- -
-67.58%
16.93%
Sales/Revenue/Turnover
- -
123.51%
8.96%
Total Cash Common Dividend
- -
- -
-7.32%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
117
160
227
255
758
2024
163
178
248
344
934
2025
178
221
263
355
1,018

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
1.21
0.54
2.91
- -
5.71
2024
0.24
1.24
0.2
- -
3.94
2025
0.95
0.97
1.43
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
1.44
2024
- -
- -
- -
- -
4.72
2025
- -
- -
- -
- -
- -
Similar Companies
Senhwa Biosciences, Inc. (6492.TWO)
ObsEva S.A. (OBSV)
Angion Biomedica Corp. (ANGN)
PreveCeutical Medical Inc. (PRVCF)
Biotron Limited (BIT.AX)
Sequenom Inc. (SQNM)
Business
Ever Supreme Bio Technology Co., Ltd (6712.TWO) is a Taiwan-based biotechnology company that specializes in the research, development, manufacturing, and sale of bio-functional materials and health-related products. The company offers a range of core products including nano-silver antimicrobial agents, far-infrared ceramic powders, negative ion products, health supplements such as probiotics and collagen formulations, and bio-based skincare and personal care items; it also provides custom OEM/ODM services for functional textiles, medical fabrics, and environmental purification solutions. Operations focus on the health and wellness sector, targeting consumer markets in Asia with emphasis on antimicrobial technologies and functional materials for apparel, healthcare, and daily consumer goods. Founded in 2001 and headquartered in Taoyuan City, Taiwan, the company maintains production facilities primarily in Taiwan and distributes products across domestic and international markets including China, Southeast Asia, and select global regions through partnerships and e-commerce channels. It operates as an independent entity listed on the Taipei Exchange, with no major disclosed subsidiaries or parent relationships. In recent developments, Ever Supreme Bio Technology expanded its product portfolio with new launches of advanced probiotic supplements and silver ion-based antimicrobial coatings in 2024, aimed at post-pandemic hygiene demands. The company secured strategic collaborations with textile manufacturers for integrating bio-functional materials into sustainable fabrics and reported revenue growth from health supplement sales amid rising consumer interest in immunity-boosting products. No significant acquisitions, funding rounds, or reorganizations have been announced in the past two years, reflecting steady operational focus on core bio-technology innovations.